Methods and kits for the diagnosis of prostate cancer
AssigneeFundacio Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada
InventorsAndreas Doll, Marina Rigau Resina, Miguel Abal Posada, Juan Morote Robles, Jaume Reventós Puigjaner
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of PSGR, a member of the G-protein-coupled olfactory receptor family which is over-expressed in prostate cancer tissue, as a marker suitable for an urine-based diagnostic test for prostate cancer which require only typical prostate manipulation and sample acquisition scenarios avoiding invasive tissue collection.
Claims24
A method for the diagnosis of prostate cancer in a subject comprising
- (i) determining the levels of PSGR mRNA in a biofluid from said subject wherein said biofluid is selected from the group consisting of urine, prostatic secretions and ejaculate and
- (ii) comparing the levels obtained in step (i) with reference values of said mRNA
- wherein increased levels of PSGR mRNA with respect to the reference value is indicative that the subject suffers prostate cancer.
A method for assessing or monitoring the response to a therapy in a subject having prostate cancer (PCa) which comprises
- (i) determining the expression levels of the PSGR mRNA in an biofluid sample from said subject after administering said therapy wherein said biofluid is selected from the group consisting of urine, prostatic secretions and ejaculate and
- (ii) comparing the levels obtained in step (i) with reference value for said mRNA obtained prior to administration of the therapy
- wherein a significant decrease or lack of change in the PSGR mRNA levels for said gene in the biofluid after the administration of said therapy in comparison with the level of expression of each of said genes prior to the administration of the therapy in the subject sample is indicative that the therapy administered to the subject is efficacious or wherein a significant increase in the PSGR mRNA levels for said gene in the biofluid after the administration of said therapy in comparison with the level of expression of each of said genes prior to the administration of the therapy in the subject sample is indicative that the therapy administered to the subject is inefficacious.
A method for monitoring the progression of prostate cancer (PCa) in a subject comprising
- (i) determining the expression levels of the PSGR mRNA in an sample from said subject wherein said biofluid is selected from the group consisting of urine, prostatic secretions and ejaculate and
- (ii) comparing the levels obtained in step (i) with reference value for said mRNA obtained from the same subject at an earlier time point of the disease
- wherein a significant decrease or lack of change in the PSGR mRNA for said gene in the biofluid in comparison with the level of expression of said mRNA at the earlier time point is indicative that the prostate cancer is not progressing or
- wherein a significant increase in the PSGR mRNA for said gene in the biofluid in comparison with the level of expression of said mRNA at the earlier time point is indicative that the prostate cancer is progressing.
Dependencies are inferred from the claim text.